Research graph
References from Disproportionality analysis of cardiovascular adverse events reported to the FDA adverse event monitoring system with monoclonal antibodies targeting type 2 inflammation. Local targets link to admitted publications; unresolved targets remain external evidence.
Type 2 inflammation in asthma–present in most, absent in many
10.1038/nri3786 · 2015 · External reference
Type 2 inflammation in asthma and other airway diseases
10.1183/23120541.00576-2021 · 2022 · External reference
Safety of biological therapies for severe asthma: an analysis of suspected adverse reactions reported in the WHO pharmacovigilance database
10.1007/s40259-024-00653-6 · 2024 · External reference
Biologic therapies for severe asthma
10.1056/nejmra2032506 · 2022 · External reference
Targeting the interleukin-5 pathway for treatment of eosinophilic conditions other than asthma
10.3389/fmed.2018.00049 · 2018 · External reference
Biologic therapies in severe asthma: current landscape, clinical evidence, and future directions
10.1007/s40124-025-00373-7 · 2025 · External reference
Current summary of clinical studies on anti-TSLP antibody, tezepelumab, in asthma
10.1016/j.alit.2022.11.006 · 2023 · External reference
Anaphylactic risks associated with immunobiological agents in asthma therapy
10.1590/1806-9282.20221358 · 2023 · External reference
Potential cancer risk with omalizumab? a disproportionality analysis of the WHO's VigiBase pharmacovigilance database
10.1111/all.15008 · 2021 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Cardiovascular adverse effects of anti-IL-5/IL-5Ralpha therapies: a real-world study
10.1016/j.jaip.2020.12.031 · 2021 · External reference
Assessing the association between omalizumab and arteriothrombotic events through spontaneous adverse event reporting
10.2147/jaa.s29811 · 2012 · External reference
FDA adverse event Reporting System (FAERS) essentials: a guide to understanding, applying, and interpreting adverse event data reported to FAERS
10.1002/cpt.3701 · 2025 · External reference
The strengthening the reporting of observational studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
10.7326/0003-4819-147-8-200710160-00010 · 2007 · External reference
The STROBE reporting checklist
2025 · External reference
A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions
10.1002/pds.668 · 2002 · External reference
Baseline characteristics of patients enrolled in EXCELS: a cohort study
10.1016/s1081-1206(10)60184-6 · 2009 · External reference
Mechanisms driving gender differences in asthma
10.1007/s11882-017-0686-1 · 2017 · External reference
Cardiovascular and cerebrovascular events among patients receiving omalizumab: results from EXCELS, a prospective cohort study in moderate to severe asthma
10.1016/j.jaci.2016.07.038 · 2017 · External reference
A case of pulmonary vein thrombosis associated with treatment of Omalizumab
2017 · External reference
Omalizumab as a provoking factor for venous thromboembolism
10.1177/1177392819861987 · 2019 · External reference
Cardiovascular safety of biologic therapies in patients with severe asthma: a nationwide cohort study in Belgium
2025 · External reference
Relevance of the Weber effect in contemporary pharmacovigilance of oncology drugs
10.2147/tcrm.s137144 · 2017 · External reference
Interleukin-13 protects from atherosclerosis and modulates plaque composition by skewing the macrophage phenotype
10.1002/emmm.201201374 · 2012 · External reference
Interleukin 4: its role in hypertension, atherosclerosis, valvular, and nonvalvular cardiovascular diseases
10.1177/1074248419868699 · 2020 · External reference
IL-4 and IL-13 in cardiovascular disease: from immune modulation to therapeutic possibilities - a narrative review
10.2147/jir.s531346 · 2025 · External reference
Cardiovascular safety of dupilumab: current evidence and emerging concerns
10.3390/allergies6010010 · 2026 · External reference
MELTEMI and COLUMBA: 5-year comparative safety analysis of benralizumab and mepolizumab
10.1016/j.jaip.2024.04.033 · 2024 · External reference
Long-term efficacy and safety of Mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study
10.1016/j.clinthera.2016.07.010 · 2016 · External reference
Long-term safety and clinical benefit of Mepolizumab in patients with the most severe eosinophilic asthma: the COSMEX study
10.1016/j.clinthera.2019.07.007 · 2019 · External reference
A real-world disproportionality analysis of mepolizumab based on the FDA adverse event reporting system
10.3389/fphar.2023.1280490 · 2023 · External reference
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study
10.1016/s2213-2600(22)00492-1 · 2023 · External reference
Omalizumab safety concerns
10.1016/j.jaci.2024.11.005 · 2025 · External reference
